STEGLATRO is approved.
Prescription savings for STEGLATRO.
Pay as little as $0 per prescription.

Eligible, privately insured patients may pay as little as $0 per prescription on each of up to 12 qualifying prescriptions. Maximum savings are limited.

Not all patients are eligible. Certain restrictions apply. Please see Terms and Conditions.

Free 30-Day Trial Offer.

Eligible patients may print a free trial offer for their first prescription.

Not all patients are eligible. Certain restrictions apply. Please see Terms and Conditions.


Sign up to get information.
Merck's Privacy Commitment

The information you provide will be available to the Merck & Co., Inc., family of companies (collectively, "Merck") and others working on behalf of Merck, to provide the information and services you request. Personal information about you will not otherwise be disclosed for marketing purposes without your permission. Merck reviews personal information and nonidentifiable information, not only to provide the requested information and services, but also to develop and offer additional services and communications that we believe our customers might find of interest. Merck also may use personal information to audit its resources for compliance and security purposes. For more information about how Merck protects personal information about you, please read our Internet Privacy Policy and Privacy Commitment for US patients, consumers, and caregivers.

 
Please complete the form below to receive more information about STEGLATROTM (ertugliflozin).
*Required Fields
Are you 18 years of age or older?*

The program is only for those 18 years of age or older. If you are 18 years of age or older, please check the “YES” button on this page.

First Name*

Required Field

Last Name*

Required Field

Address 1*

Required Field

Address 2
City*

Required Field

State*

Required Field

 
Zip Code*

Required Field

By providing your name, address, and other personal information above and clicking the SUBMIT button below, you agree to permit Merck and others working on behalf of Merck to use this information to provide you with information, resources, services, and communications about STEGLATROTM (ertugliflozin), and disease-related materials via e-mail or otherwise. Additionally, your information may be used for market research purposes.

At any time, you can request a copy of this permission and that personal information about you be removed from the Merck contact list for STEGLATRO by calling 888-776-8364. Unless you change this selection sooner, your permission will expire 1 year after Merck no longer promotes STEGLATRO.

By clicking "SUBMIT," I am signing this form. I agree that my information may be used as described above, as well as for market research purposes:

SUBMIT
Thank you.
You’re now signed up to receive updates and other resources about STEGLATROTM (ertugliflozin).


You are encouraged to report negative side effects of prescription drugs to the FDA.

This site is intended only for residents of the United States, its territories and Puerto Rico.

Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

DIAB-1226014-0000 12/17
 
Please orient your device to the portrait position to return to the site